Breaking News

Petra Pharma Licenses Takeda’s Serabelisib

Researching new approaches that have the potential to increase tumor responses with PI3K inhibitors and minimize side effects

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Petra Pharma Corporation has secured a global license from Takeda Pharmaceutical Co. to develop, manufacture and commercialize serabelisib and two additional PI3Kα-specific inhibitors. Petra has a license for all human therapeutic uses, except for a subset of undisclosed rare-disease indications, which Takeda had previously out-licensed.   Petra plans to initiate a Phase 1b/2 study with serabelisib in late 2019 to advance research and insights in PI signaling pathways with a focus on PIK3CA-m...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters